Articles by Aparna R. Parikh, MD ADCs Targeting GI Cancers By Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD Published: July 12th 2024 | Updated: July 12th 2024 Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
ADCs Targeting HER2+ Gynecologic Cancers By Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.
ADCs Targeting HER2+ Breast Cancer By Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Assessing HER2 Status Across Tumor Types By Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Unmet Needs Surrounding mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
Data Surrounding Treatment for MSI-high Patients from ASCO 2024 By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
Real-World Data Surrounding Sequencing Strategies for Refractory mCRC By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD, Scott Paulson, MD Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Considerations for Platinum-based Therapy By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Side effect profiles driven by fruquintinib use are discussed.
Consideration for Fruquintinib Dosing and Titration By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
FRESCO-2 Study Highlights By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Medical experts provide key takeaways and impacts from the FRESCO-2 study.
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Fruquintinib MoA and Toxicity Profile Overview By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Key safety considerations for the use of fruquintinib are explored.
Evaluating 3L Treatment Landscape Evolution By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Overview of Current mCRC Treatment Landscape By Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Assessing HER2 Expression in Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
